Dermatol. praxi. 2017;11(3):145-147 | DOI: 10.36290/der.2017.028
The experience with long-term secukinumab treatment
- Kožní oddělení, Masarykova nemocnice v Ústí nad Labem, o. z., Krajská zdravotní, a. s.
Psoriasis is a chronic disease that has a significant negative impact on life quality of patients and often requires long-term, sometimeslifelong, effective and safe therapy. The gradually expanding range of biological products makes it possible to significantlyimprove the treatment effect and to limit or completely eliminate the negative impact of disease on the quality of their lives.
Keywords: psoriasis, anti-TNF alpha therapy, IL-17A antagonist, etanercept, secukinumab
Published: October 1, 2017 Show citation
References
- Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, and others. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept, J. Am. Acad. Dermatol. 2017; 76: 655-661.
Go to original source... 
Go to PubMed... - van de Kerkhof PCM, Griffiths CEM, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis, J. Am. Acad. Dermatol. 2016; 75: 83-97. Go to original source... Go to PubMed...
- Bissonnette RLT, Thaçi D, Toth D, Letzelter K, Xia S, Mazur R, Milutinovic M, Leonardi C. Secukinumab demonstrates sustained high efficacy and a favorable safety profile in moderate to severe psoriasis patients through 4 years of treatment (extension of SCULPTURE study). Seminars in Cutaneous Medicine and Surgery, 2016. 35, December 2016 (Supplement 7): p. S130 - S131.
- Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study, J. Am. Acad. Dermatol. 2017; 76(1): 60-69. Go to original source... Go to PubMed...
- Reich K, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol, 2017; 176(3): p. 752-758. Go to original source... Go to PubMed...